Retrogenix, a United Kingdom-based biotechnology company, has signed a non-exclusive strategic collaboration with United States-based Resonant Therapeutics Inc to identify the targets of Resonant antibodies directed against the tumour microenvironment, it was reported yesterday.
Resonant exploits its proprietary IMPaCT tumour microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumour antibodies for difficult to treat tumours. By recapitulating the tumour microenvironment and using a live-cell, function-first approach, Resonant's platform generates therapeutic candidates that would not be discovered by other methods with unprecedented speed. The target screening performed by Retrogenix will focus on hundreds of novel, prioritised antibodies in Resonant's collection.
Jo Soden, co-managing director of Retrogenix, said, 'We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant's innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.'
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886